Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics


Liquidia Technologies, Inc. (LQDA)

Today's Latest Price: $2.90 USD

0.02 (-0.68%)

Updated Dec 4 4:00pm

Add LQDA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LQDA Stock Summary

  • Liquidia Technologies Inc's stock had its IPO on July 26, 2018, making it an older stock than only 4.6% of US equities in our set.
  • With a price/sales ratio of 20.77, Liquidia Technologies Inc has a higher such ratio than 92.55% of stocks in our set.
  • As for revenue growth, note that LQDA's revenue has grown 353.23% over the past 12 months; that beats the revenue growth of 98.08% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Liquidia Technologies Inc, a group of peers worth examining would be ETTX, EVGN, UMRX, NOVN, and SYBX.
  • LQDA's SEC filings can be seen here. And to visit Liquidia Technologies Inc's official web site, go to www.liquidia.com.

LQDA Stock Price Chart Interactive Chart >

Price chart for LQDA

LQDA Price/Volume Stats

Current price $2.90 52-week high $12.10
Prev. close $2.92 52-week low $2.65
Day low $2.85 Volume 946,700
Day high $3.00 Avg. volume 452,063
50-day MA $4.04 Dividend yield N/A
200-day MA $5.72 Market Cap 109.48M

Liquidia Technologies, Inc. (LQDA) Company Bio


Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.


LQDA Latest News Stream


Event/Time News Detail
Loading, please wait...

LQDA Latest Social Stream


Loading social stream, please wait...

View Full LQDA Social Stream

Latest LQDA News From Around the Web

Below are the latest news stories about Liquidia Technologies Inc that investors may wish to consider to help them evaluate LQDA as an investment opportunity.

Liquidia Technologies nabs new U.S. patent covering inhaled dry powder treprostinil

The USPTO has issued a Notice of Allowance to Liquidia Technologies (LQDA) for patent application No. 16/099,135, covering methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.The drug candidate is currently under review with FDA for the treatment of pulmonary arterial hypertension.The patent is expected...

Seeking Alpha | August 28, 2020

Liquidia Technologies (LQDA) Investor Presentation - Slideshow

The following slide deck was published by Liquidia Technologies, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 13, 2020

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent

RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics Corporation (UTC) filed an amended complaint in its patent infringement action under the Hatch-Waxman Act against the Company in the U.S. District Court for the District of Delaware. The amended complaint asserts infringement of an additional recently issued U.S. Patent No. 10,716,793 (‘793) allegedly relating to UTC’s Tyvaso®, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH). The lawsuit was originally filed in June 2020 in response to Li...

Yahoo | July 24, 2020

SHAREHOLDER ALERT: Halper Sadeh LLP Announces It is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:

Yahoo | July 9, 2020

Liquidia Announces Closing of Public Offering of Common Stock

Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. All of the shares in the offering were sold by Liquidia. In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less the underwriting discount and commissions.

Yahoo | July 2, 2020

Read More 'LQDA' Stories Here

LQDA Price Returns

1-mo -23.08%
3-mo -33.18%
6-mo -66.32%
1-year -28.75%
3-year N/A
5-year N/A
YTD -32.16%
2019 -80.26%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching LQDA

Want to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:

Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.8356 seconds.